Remove Life Science Remove Production Remove Radiology
article thumbnail

Four ways Biogen is tackling digital innovation in neurological disease

pharmaphorum

It can mean everything from patient-facing disease management apps and wearables to background AI dramatically altering drug discovery or radiological imaging. About half of our talents come from the life sciences industry and clinical research, and the other half come from the tech world – so, totally different backgrounds,” Hadjiat said. “We

article thumbnail

Bayer delivers on medical innovation fueling transformation of pharma business

The Pharma Data

Our leadership in cardiology, radiology and women’s health is recognized worldwide, and we are expanding our presence in oncology, working tirelessly to bring forward new approaches that can change the treatment paradigm for patients,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Packaging Solutions for Pharmaceuticals & Medical Devices: Insights and Considerations

XTalks

A container closure system consists of all the packaging components that contain and protect a pharmaceutical product. A container closure system protects the product from environmental conditions, safeguarding a product’s purity, strength, safety and efficacy. Container Closure Systems. shaking, changes in pressure, etc.).

article thumbnail

Considerations for Mobile Health Technology Developers: Part 2

pharmaphorum

On 27th September 2022, the Food and Drug Administration (FDA) issued its final guidance for industry and FDA staff clinical decision support (CDS) software, which has been anticipated since the Center for Devices and Radiological Health (CDRH) listed the guidance as a top priority for fiscal year 2022.

article thumbnail

3 Newest COVID-19 Tests Authorized by the FDA

XTalks

The products encompass molecular, antigen and T cell-based testing approaches. The FDA continues to prioritize the availability of more at-home testing options in response to the pandemic,” said Jeff Shuren, MD, JD, director of the FDA’s Center for Devices and Radiological Health in a press announcement from the agency.

Protein 98
article thumbnail

Rezzayo (Rezafungin) Becomes First New Treatment Option for Candidemia and Invasive Candidiasis in Over a Decade

XTalks

The antifungal drug was approved under Priority Review based on its Qualified Infection Disease Product designation , an incentive to promote development of antifungals for life-threatening infections. Candidemia is a bloodstream infection caused by the Candida yeast and is a common form of invasive candidiasis.

article thumbnail

New Diagnostic Drug Flyrcado Enhances Coronary Artery Disease Diagnosis

XTalks

These products exemplify the company’s ongoing efforts to advance molecular imaging. Recently, Lumicell’s imaging platform received dual FDA approval for its Lumisight optical imaging agent and Lumicell Direct Visualization System (DVS), further showcasing advancements in imaging technologies across different cancer indications.